Replimune’s mission is to revolutionize cancer treatment through comprehensive activation of a tumor-specific immune response. Founded by the original team from Biovex (acquired by Amgen) Replimune is pioneering a new class of oncolytic patient-specific immune response both locally at the site of the injected tumor and systemically throughout the body. Replimune’s therapies are designed to not just treat a patient’s cancer, but also vaccinate against future relapse. Through oncolytic immunotherapy, Replimune aims to both eradicate tumors today and prevent relapse in the future.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.